Works matching IS 21534888 AND DT 2023 AND VI 14 AND IP 1
Results: 18
Supportive Care and Management of Complications in BTCs: A Multidisciplinary Team Approach.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 14
- Publication type:
- Article
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 13
- By:
- Publication type:
- Article
Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 12
- Publication type:
- Article
Brukinsa Now FDA Approved for Patients with CLL or SLL.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 11
- Publication type:
- Article
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 11
- Publication type:
- Article
CTC Count May Help Physicians Choose Treatment for Patients with Metastatic Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 11
- By:
- Publication type:
- Article
NEW INDICATIONS: Keytruda Received FDA Approval for Adjuvant Treatment of NSCLC.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 10
- Publication type:
- Article
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 7
- By:
- Publication type:
- Article
Krazati Receives Accelerated FDA Approval for NSCLC with KRAS<sup>G12C</sup> Mutation.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 7
- Publication type:
- Article
Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 6
- By:
- Publication type:
- Article
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 6
- Publication type:
- Article
FDA Grants Lunsumio Accelerated Approval for Relapsed or Refractory Follicular Lymphoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 6
- Publication type:
- Article
Jaypirca Receives FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 5
- Publication type:
- Article
NEW DRUGS: Orserdu FDA Approved for ER-Positive, Advanced or Metastatic Breast Cancer with ESR1 Mutation.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 5
- Publication type:
- Article
Ribociclib plus Endocrine Regimen Outperforms Combination Chemotherapy in Advanced Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article
Survey Results Provide Insights into Biosimilar Use at Cancer Centers.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article
Adding Radiation to Systemic Therapy Improves Survival in Patients with Advanced Hepatocellular Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article